Whittier Trust Co. Sells 144 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Whittier Trust Co. lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 35.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 264 shares of the medical research company’s stock after selling 144 shares during the period. Whittier Trust Co.’s holdings in Charles River Laboratories International were worth $49,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in CRL. Versant Capital Management Inc lifted its position in shares of Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after buying an additional 150 shares during the period. Pinnacle Bancorp Inc. raised its stake in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares in the last quarter. Tortoise Investment Management LLC lifted its holdings in shares of Charles River Laboratories International by 77.7% during the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 115 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at $59,000. Finally, ORG Wealth Partners LLC bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth about $56,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on CRL. JPMorgan Chase & Co. reduced their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. The Goldman Sachs Group cut Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their price target for the company from $190.00 to $170.00 in a report on Friday. Barclays reduced their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 18th. Finally, Morgan Stanley lowered their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and a consensus target price of $189.77.

Insider Transactions at Charles River Laboratories International

In other news, CEO James C. Foster purchased 6,075 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the transaction, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, COO Birgit Girshick acquired 1,514 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average price of $164.63 per share, with a total value of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $167.29 on Tuesday. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $273.57. The company’s 50-day moving average is $165.66 and its two-hundred day moving average is $183.49. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company has a market cap of $8.55 billion, a PE ratio of 1,115.28, a PEG ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same period last year, the firm earned $2.46 earnings per share. The business’s revenue for the quarter was down 1.1% on a year-over-year basis. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).